Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633863 | 0.77 | CYP3A4 (0.59) | STSCYP3A4ESR1ESR2POLB | |
| SCHEMBL30526132 | 0.76 | STS (0.46) | STSCYP3A4CA1CA2CA9 | |
| SCHEMBL29812596 | 0.75 | STS (0.51) | STSCYP3A4CA1CA2CA9 | |
| SCHEMBL1243178 | 0.75 | STS (0.51) | STSCYP3A4CA1CA2CA9 | |
| SCHEMBL29003517 | 0.72 | CYP3A4 (0.45) | STSCYP3A4CA1CA2CA9 | |
| SCHEMBL8006865 | 0.71 | STS (0.49) | STSCYP3A4CA1CA2CA9 | |
| Propionic Acid SCHEMBL28865642 | 0.71 | CYP3A4 (0.47) | STSCYP3A4ESR1ESR2POLB | |
| SCHEMBL9477894 | 0.70 | CYP3A4 (0.50) | STSCYP3A4CA1CA2CA9 | |
| SCHEMBL5664523 | 0.70 | ALDH1A1 (0.54) | STSCYP3A4CA1CA2CA9 | |
| Naphthalene SCHEMBL10357718 | 0.69 | STS (0.50) | STSCYP3A4CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210330614-A1 | PROCESS FOR MANUFACTURING PHENYLEPHRINE RESINATE PARTICLES; PHENYLEPHRINE RESINATE PARTICLES; AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONS | JOHNSON & JOHNSON CONSUMER INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210322558-A1 | PHENYLEPHRINE RESINATE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | JOHNSON & JOHNSON CONSUMER INC. | 2021-10-21 | — | — | US | disclosed |
| EP-2968224-B1 | PHENYLEPHRINE RESINATE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | JOHNSON & JOHNSON CONSUMER INC (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-2968223-B1 | PHENYLEPHRINE RESINATE PARTICLES | JOHNSON & JOHNSON CONSUMER INC (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3229787-A1 | PROCESS FOR MANUFACTURING PHENYLEPHRINE RESINATE PARTICLES; PHENYLEPHRINE RESINATE PARTICLES; AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONS | Johnson & Johnson Consumer Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2968188-B1 | COATED PHENYLEPHRINE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | JOHNSON & JOHNSON CONSUMER INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20160166518-A1 | PROCESS FOR MANUFACTURING PHENYLEPHRINE RESINATE PARTICLES PHENYLEPHRINE RESINATE PARTICLES AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONS | JOHNSON & JOHNSON CONSUMER INC. | 2016-06-16 | — | — | US | disclosed |
| WO-2016094751-A1 | PROCESS FOR MANUFACTURING PHENYLEPHRINE RESINATE PARTICLES; PHENYLEPHRINE RESINATE PARTICLES; AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONS | JOHNSON & JOHNSON CONSUMER INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| EP-2968223-A1 | PHENYLEPHRINE RESINATE PARTICLES | Johnson & Johnson Consumer Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968188-A1 | COATED PHENYLEPHRINE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | Johnson & Johnson Consumer Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968224-A1 | PHENYLEPHRINE RESINATE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | Johnson & Johnson Consumer Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014149526-A1 | PHENYLEPHRINE RESINATE PARTICLES | MCNEIL-PPC, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014149525-A1 | PHENYLEPHRINE RESINATE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | MCNEIL-PPC, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014149529-A1 | COATED PHENYLEPHRINE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | MCNEIL-PPC, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140271891-A1 | PHENYLEPHRINE RESINATE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | MCNEIL-PPC, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271893-A1 | COATED PHENYLEPHRINE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | MCNEIL-PPC, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271892-A1 | PHENYLEPHRINE RESINATE PARTICLES HAVING GOOD AUC | MCNEIL-PPC, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271891-A1 | PHENYLEPHRINE RESINATE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | REN, ADRB1, ADRA2C | STS 3964/4885CYP3A4 115/4885CA1 4518/4885 |
| US-20210330614-A1 | PROCESS FOR MANUFACTURING PHENYLEPHRINE RESINATE PARTICLES; PHENYLEPHRINE RESINATE PARTICLES; AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONS | ADRA1A, PSAP, PEF1 | STS 3849/4885CYP3A4 178/4885CA1 4691/4885 |
| US-20140271893-A1 | COATED PHENYLEPHRINE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | ADRA2C, ADRA2A, PDE3A | STS 4594/4885CYP3A4 118/4885CA1 4609/4885 |
| US-20160166518-A1 | PROCESS FOR MANUFACTURING PHENYLEPHRINE RESINATE PARTICLES PHENYLEPHRINE RESINATE PARTICLES AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONS | PSAP, ADRA1A, PEF1 | STS 3904/4885CYP3A4 243/4885CA1 4598/4885 |
| US-20140271892-A1 | PHENYLEPHRINE RESINATE PARTICLES HAVING GOOD AUC | ADRB1, ADRA1A, ADRA2A | STS 4458/4885CYP3A4 56/4885CA1 4706/4885 |
| US-20210322558-A1 | PHENYLEPHRINE RESINATE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | REN, ADRB1, ADRA2C | STS 3964/4885CYP3A4 115/4885CA1 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.